These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

313 related items for PubMed ID: 7669939

  • 1. Apomorphine in patients with Parkinson's disease.
    Muguet D, Broussolle E, Chazot G.
    Biomed Pharmacother; 1995; 49(4):197-209. PubMed ID: 7669939
    [Abstract] [Full Text] [Related]

  • 2. A review of intermittent subcutaneous apomorphine injections for the rescue management of motor fluctuations associated with advanced Parkinson's disease.
    Chen JJ, Obering C.
    Clin Ther; 2005 Nov; 27(11):1710-24. PubMed ID: 16368444
    [Abstract] [Full Text] [Related]

  • 3. [Apomorphine for treatment of "off-periods" in Parkinson's disease].
    Zoldan J, Merims D, Kuritzky A, Ziv I, Melamed E.
    Harefuah; 1999 Nov 15; 137(10):444-6, 512, 511. PubMed ID: 10959339
    [Abstract] [Full Text] [Related]

  • 4. Subcutaneous apomorphine : an evidence-based review of its use in Parkinson's disease.
    Deleu D, Hanssens Y, Northway MG.
    Drugs Aging; 2004 Nov 15; 21(11):687-709. PubMed ID: 15323576
    [Abstract] [Full Text] [Related]

  • 5. Apomorphine hydrochloride for the treatment of Parkinson's disease.
    Unti E, Ceravolo R, Bonuccelli U.
    Expert Rev Neurother; 2015 Nov 15; 15(7):723-32. PubMed ID: 26037961
    [Abstract] [Full Text] [Related]

  • 6. Effect of subcutaneous apomorphine on tremor in idiopathic Parkinson's disease.
    Hellmann MA, Sabach T, Melamed E, Djaldetti R.
    Biomed Pharmacother; 2008 Nov 15; 62(4):250-2. PubMed ID: 17967525
    [Abstract] [Full Text] [Related]

  • 7. Sublingual apomorphine: a new pharmacological approach in Parkinson's disease?
    Montastruc JL, Rascol O, Senard JM, Houin G, Rascol A.
    J Neural Transm Suppl; 1995 Nov 15; 45():157-61. PubMed ID: 8748621
    [Abstract] [Full Text] [Related]

  • 8. [Apomorphine in off state--clinical experience].
    Rudzińska M, Szczudlik A.
    Neurol Neurochir Pol; 2007 Nov 15; 41(2 Suppl 1):S40-8. PubMed ID: 17941458
    [Abstract] [Full Text] [Related]

  • 9. [Subcutaneous apomorphine in the treatment of Parkinson's disease].
    Linazasoro G.
    Neurologia; 1994 Jan 15; 9(1):1-3. PubMed ID: 8161461
    [Abstract] [Full Text] [Related]

  • 10. [Subcutaneous administration of apomorphine in motor fluctuations in Parkinson's disease].
    Pollak P, Champay AS, Gaio JM, Hommel M, Benabid AL, Perret J.
    Rev Neurol (Paris); 1990 Jan 15; 146(2):116-22. PubMed ID: 2320817
    [Abstract] [Full Text] [Related]

  • 11. Apomorphine continuous stimulation in Parkinson's disease: receptor desensitization as a possible mechanism of reduced motor response.
    Maggio R, Barbier P, Corsini GU.
    J Neural Transm Suppl; 1995 Jan 15; 45():133-6. PubMed ID: 8748618
    [Abstract] [Full Text] [Related]

  • 12. Update on apomorphine for the rapid treatment of hypomobility ("off") episodes in Parkinson's disease.
    Obering CD, Chen JJ, Swope DM.
    Pharmacotherapy; 2006 Jun 15; 26(6):840-52. PubMed ID: 16716137
    [Abstract] [Full Text] [Related]

  • 13. [Subcutaneous apomorphine infusion in the treatment of Parkinson disease].
    Albani C, Zangger I, Fischer G.
    Schweiz Rundsch Med Prax; 1992 Aug 25; 81(35):1011-5. PubMed ID: 1410978
    [Abstract] [Full Text] [Related]

  • 14. Apomorphine test in de novo Parkinson's disease.
    Bonuccelli U, Piccini P, Del Dotto P, Pavese N, D'Antonio P, Muratorio A.
    Funct Neurol; 1992 Aug 25; 7(4):295-8. PubMed ID: 1427361
    [Abstract] [Full Text] [Related]

  • 15. [Apomorphine in treatment of Parkinson's disease with fluctuations].
    Zaleska B, Domzał T.
    Neurol Neurochir Pol; 1999 Aug 25; 33(6):1297-303. PubMed ID: 10791032
    [Abstract] [Full Text] [Related]

  • 16. Recent advances in the clinical pharmacology of Parkinson's disease.
    Montastruc JL.
    Therapie; 1991 Aug 25; 46(4):293-303. PubMed ID: 1683024
    [Abstract] [Full Text] [Related]

  • 17. Apomorphine test for dopaminergic responsiveness: a dose assessment study.
    Bonuccelli U, Piccini P, Del Dotto P, Rossi G, Corsini GU, Muratorio A.
    Mov Disord; 1993 Apr 25; 8(2):158-64. PubMed ID: 8474482
    [Abstract] [Full Text] [Related]

  • 18. Apomorphine monotherapy in the treatment of refractory motor complications of Parkinson's disease: long-term follow-up study of 64 patients.
    Manson AJ, Turner K, Lees AJ.
    Mov Disord; 2002 Nov 25; 17(6):1235-41. PubMed ID: 12465062
    [Abstract] [Full Text] [Related]

  • 19. Levodopa treatment does not affect low-dose apomorphine test in patients with Parkinson's disease.
    Happe S, Tings T, Helmschmied K, Neubert K, Wuttke W, Paulus W, Trenkwalder C.
    Mov Disord; 2004 Dec 25; 19(12):1511-5. PubMed ID: 15390061
    [Abstract] [Full Text] [Related]

  • 20. [The apomorphine test for diagnosis of parkinsonian syndrome].
    Piccini P, Del Dotto P, Napolitano A, Pardini C, Bonuccelli U.
    Riv Neurol; 1990 Dec 25; 60(6):221-3. PubMed ID: 2100046
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.